Dexcom stock heads into the open after a 2.0% gain

At the close on September 15, 2026, Dexcom stock finished the Nasdaq session higher at USD 84.68, up 2.0 percent, after announcing its selection for an FDA digital health pilot program. The move outpaced the Nasdaq Composite, which fell 0.8 percent that day.

Dexcom stock closed at USD 84.68 on the Nasdaq on September 15, 2026, up 1.99 percent from the prior session.

That advance contrasted with a weaker technology backdrop, as the Nasdaq Composite lost about 0.8 percent on the same day.

September 15, 2026 in numbers

Dexcom Inc. (ISIN US2521311074, Nasdaq: DXCM) saw its shares move within a daily range between USD 83.26 and USD 85.90 on September 15, 2026, according to Robinhood data.

Per that same Robinhood overview, Dexcom closed the session at USD 84.68, finishing roughly 1.7 percent below the intraday high and around 1.7 percent above the day low.

This performance stood out against the broader Nasdaq Composite, which ended September 15, 2026 down 0.78 percent with a close near 25,982 points, reflecting pressure from higher oil prices and rising Treasury yields as summarized in market wrap reports.

As StockTitan noted in a filing summary dated September 15, 2026, Dexcom was announced as the first participant selected for the FDA TEMPO Digital Health Devices Pilot Program, a development that provided a concrete positive backdrop for the stock in the latest session.

Today's drivers and events

Today, September 16, 2026, investors can still factor in the FDA pilot program announcement, which highlights regulatory engagement with Dexcom's digital health technology and may continue to shape sentiment around the stock.

Broader market conditions remain important as well, with recent commentary pointing to elevated oil prices and higher Treasury yields weighing on United States equity indexes, a context that could influence trading in health care and technology names such as Dexcom as the next Nasdaq session gets under way.